Materials and Methods:
The renal tumor database of Gazi University, Medical Faculty Hospital, Department of Urology was retrospectively reviewed. This study was reviewed and approved by the medical ethics committee of Gazi University School Of Medicine on 9 July 2018 (approval number: 542). Patients younger than 18 years of age, those with a previous history of surgical operation due to kidney tumors, hereditary or family history of malignancy other than RCC were excluded from the study. After obtaining informed surgical consent, 151 patients who underwent radical or partial nephrectomy between 2010 and 2018 for kidney tumor were included in the study. Patient information was collected from patient files and the hospital automation system. The missing information was completed by reaching the patients or their relatives through their phones registered in the hospital system. MetS was defined based on the National Cholesterol Education Program Adult Treatment Panel-III  (NCEP/ATP III) criteria [1]. These criteria are as follows: elevated serum TGL (≥150 mg/dl), low HDL cholesterol (<40 mg/dl in males, 50 mg/dl in females), HT (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg), high fasting plasma glucose (≥110 mg/dl), waist circumference ≥102 cm for males and ≥80 cm for females. In the presence of 3 of these 5 criteria, patients are considered to have metabolic syndrome. In our study, the body mass index (BMI) of the patients was used instead of waist circumference. The patients were grouped based on the presence and absence of MetS, as well as the presence and absence of MetS components. The groups were analyzed according to age, gender, tumor size, pathological T stage, Fuhrman grade, high density lipoprotein (HDL) and triglycerid (TGL) levels, HT, and DM status. The American Joint Comittee on Cancer 2017 RCC tumor-node-metastasis (TNM) staging system was used for the pathological T stage, and the 2016 WHO classification of RCC subtypes was used for the histological subtype [14,15] .